Scholar Rock Holding Corporation

SRRK Healthcare Biotechnology

Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.

EPS
+14.3%
Free cash flow
+8.88%
Total debt
+294.3%

Quarter to June 2026, against a year earlier

46.94 1.44 +3.16%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
−7.3×
Dividend yield
—
F-score
3/9
Altman Z
1.14
Beneish M
n/a
Dividend safety
n/a

Scholar Rock Holding Corporation (SRRK) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a P/B ratio of 24.2×. Over the past ten years it has ranged from 0.0× (June 2018) to 56.0× (December 2024); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2022 2.2× (58.59%)
FY2021 5.3× (7.34%)
FY2020 5.7× 77.92%
FY2019 3.2× —
FY2016 0.0× —

Quarterly newest first

Period P/B ratio Change
Mar 2022 2.8× (46.82%)
Dec 2021 5.3× (18.07%)
Sep 2021 6.5× 32.55%
Jun 2021 4.9× (36.31%)
9 more quarters

Against its own ten years

Low 0.0× High 56.0×
Ten-year median 5.3×
Current reading's percentile 93

P/B ratio against peers

Company P/B ratio
PTCT PTC Therapeutics, Inc. compare n/m
CGON CG Oncology, Inc. compare 5.6×
MANE Veradermics Incorporated compare 6.4×
BLTE Belite Bio, Inc. Sponsored ADR compare 7.5×
IMVT Immunovant, Inc. compare 8.0×
COGT Cogent Biosciences, Inc. compare 10.9×
ERAS Erasca, Inc. compare 11.5×
SRRK Scholar Rock Holding Corporation 23.5×
KOD Kodiak Sciences Inc. compare 94.0×
Biotechnology industry median 2.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on SRRK